Hospital General de Castellón-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2023

  1. Short-Term Changes in Peak VO2 After Initiation of Dapagliflozin in Heart Failure Across Iron Status

    JACC: Heart Failure, Vol. 11, Núm. 11, pp. 1611-1622

  2. Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO2 study

    Frontiers in Cardiovascular Medicine, Vol. 10

2022

  1. Bending oxygen saturation index and risk of worsening heart failure events in chronic heart failure

    European Journal of Heart Failure, Vol. 24, Núm. 11, pp. 2108-2117

2021

  1. Proteinuria-lowering effects of proprotein convertase subtilisin/kexin type 9 inhibitors in chronic kidney disease patients: A real-world multicentric study

    Metabolites, Vol. 11, Núm. 11

2018

  1. Early effects of empagliflozin on exercise tolerance in patients with heart failure: A pilot study

    Clinical Cardiology, Vol. 41, Núm. 4, pp. 476-480